The optimal treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)/COVID‐19 is unknown. 1 We report the case of a previously fit 27‐year‐old male who presented with a 3‐day history of fever (>39 C), swollen, erythematous elbows and no respiratory symptoms. His white blood count (WBC) was 187×10 9 /L and bone marrow (Figure 1A & 1C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 ( FLT3 ) internal tandem duplication (ITD), wild‐type NPM1 and no additional mutations on a next‐generation sequencing panel.

No abstract

No abstract

No abstract